Abstract:Abstract Background and Aims Membranous nephropathy (MN) is one of the most common causes of nephrotic syndrome in non-diabetic adults, accounting for almost 30% of biopsy-diagnoses. The degree of proteinuria varies widely from sub-nephrotic (less than 3.5 g/day) to more than 20 g/day. Patients with primary MN who attain either spontaneous or treatment-induced remission, generally, have a good long-term prognosis. Those who reach partial remission fare better than those with stable or progressive disease, while duration of remission- whether spontaneous or due to treatment is linked to better renal outcomes. This study aims to study long-term outcomes in MN patients, identifying risk factors of relapse and treatment non-responsiveness. Method The retrospective cohort study included 40 patients, with available data, diagnosed with primary MN between 2013 and 2023. Data on urinary protein to creatinine ratio (UPCR), serum albumin, estimated glomerular filtration rate (e-GFR), anti-PLA2R-Antibodies (PLA2R-Ab), CD19+ subpopulations, and lipid profile were collected, alongside treatment types over five years. Baseline date was defined as the date of renal biopsy, primary renal diagnosis, or symptom onset. We defined complete remission, partial remission, and relapse based on UPCR: complete remission as a UPCR of less than 300 mg/g, partial remission as a UPCR of less than 3.5 g/g provided there is also a 50% or greater reduction from the baseline UPCR, and relapse as a UPCR greater than 3.5 g/g after a period in which complete or partial remission was achieved. We monitored patients for clinical signs of remission, relapse, and non-response to treatment. Logistic regression was used to identify risk factors for remission and relapse. Additionally, a survival analysis was conducted with the primary endpoint being time to a 40% reduction in e-GFR. Results The mean age at baseline was 55.5 ± 13.2 years, with 70% being men. Mean proteinuria was 11 ± 7.5 g/g, with 75% presenting with nephrotic syndrome, while 34% of them had positive anti-PLA2R Ab. Baseline e-GFR was 75 ± 30.5 ml/min/1.73 m2. 15% (6/40) of patients did not require immunosuppressive treatment and experienced spontaneous remission. 44% (18/40) of total patients received treatment with Rituximab, 35% (14/40) received treatment with modified ponticelli regimen, while the remaining 2 patients required more than 2 different treatments to achieve remission. Complete remission was achieved by 42% of the patients, 41% achieved only partial remission, while the rest 17% did not attain remission. Relapse occurred in 32% of the patients, requiring further immunosuppressive therapy. Positive anti-PLA2R Ab (exp (B) = 15.1 p-value = 0.031) and male gender (exp (B) = 2, =.3 p-value = 0.01) were associated with higher risk of non-response to treatment. Over a follow-up of 5 years, patients with partial remission had a 26-fold times increased risk of relapse (p-value = 0.023,) compared to those with complete remission. Higher baseline UPCR also correlated with an increased relapse risk; a 1g/g increase in UPCR raised relapse risk by 17% (p-value = 0.016, exp (B) = 1.174). Kaplan-Meier survival curves demonstrated that patients achieving any form of remission did not experience the endpoint of 40% reduction in e-GFR (log-rank p-value = 0.007). Conclusion These analyses indicate that achieving and maintaining remission in primary MN is key for preserving e-GFR and preventing kidney progression. Risk factors like male gender, initial heavy proteinuria, and positive PLA2R antibodies need special attention and careful management to optimize patient outcomes.

[Abnormal movements in a case of extrapontine myelinolysis. Review of the literature].

The Application of Podocyte Antigen PLA2R and Anti-Pla2r Antibody in the Diagnosis and Treatment of Membranous Nephropathy

Urine PLA2R Antibody Detection in Hazard Stratification of PLA2R-Associated Membranous Nephropathy.

Trypsin inhibitor; determination and heat destruction of the trypsin inhibitor of soybeans.

Quantitative Detection of Anti-Pla2r Antibodies Targeting Different Epitopes and Its Clinical Application in Primary Membranous Nephropathy.

Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy

Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.

Sexual dimorphic response to rituximab treatment: A longitudinal observational study in a large cohort of patients with primary membranous nephropathy and persistent nephrotic syndrome

Therapeutic approaches to drug targets in hyperlipidemia

Endoscopic ultrasonography in the differential diagnosis of giant gastric folds.

#2012 Long term outcomes in patients with primary membranous nephropathy: a retrospective cohort study from a single center

Clinicopathological Characteristics and Outcomes of PLA2R-Associated Membranous Nephropathy in Seropositive Patients Without PLA2R Staining on Kidney Biopsy

Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy

Rituximab Immunomonitoring Predicts Remission in Membranous Nephropathy

Disease-Specific Treatment For Primary Membranous Nephropathy: The Role of Monoclonal Antibodies

Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort

PLA2R-IgG4 antibody as a predictive biomarker of treatment effectiveness and prognostic evaluation in patients with idiopathic membranous nephropathy: a retrospective study

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

#514 Efficacy of Continues Low Dose Rituximab in PLA2R-associated Primary Membranous Nephropathy

Efficacy and safety of rituximab in patients with PLA2R associated membranous nephropathy and resolved HCV infection

Association of Serum Mannose-Binding Lectin, Anti-Phospholipase A2 Receptor Antibody and Renal Outcomes in Idiopathic Membranous Nephropathy and Atypical Membranous Nephropathy: a Single Center Retrospective Cohort Study.